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Abstract Novelmetal complexes have received great
attention in the last decades due to their potential
anticancer activity. Notably, ruthenium-based com-
plexes have emerged as good alternative to the currently
used platinum-based drugs for cancer therapy, provid-
ing less toxicity and side effects to patients. Glioblas-
toma is an aggressive and invasive type of brain tumor
and despite of advances is the field of neurooncology
there is no effective treatment until now. Therefore, we
sought to investigate the potential antiproliferative
activity of phosphine-ruthenium-based complexes on
human glioblastoma cell lines. Due to its octahedral
structure as opposed to the square-planar geometry of
platinum(II) compounds, ruthenium(II) complexes
exhibit different structure–function relationship proba-
bly acting through a different mechanism from that of
cisplatin beyond their ability to bind DNA. To better
improve the pharmacological activity of metal com-
plexes we hypothesized that neutron activation of
ruthenium in the complexes would allow to decrease
the effective concentration of the compound needed to
kill tumor cells. Herein we report on the effect of
unmodified and neutron activated phosphine ruthenium
II complexes on glioblastoma cell lines carrying wild-
type and mutated p53 tumor suppressor gene. Induction
of apoptosis/authophagy as well as generation of
reactive oxygen species were determined. The phos-
phine ruthenium II complexes tested were highly active
against glioblastoma cell lines inducing cell death both
through apoptosis and autophagy in a p53 independent
fashion. Neutron activation of ruthenium compounds
rendered them more active than their original counter-
parts suggesting a new strategy to improve the antitumor
activity of these compounds.
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Introduction
Ruthenium has attracted much attention in the last
decades as components of new transition-metal-based
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antitumor drugs (Clarke 2003; Zhang and Lippard
2003). Several studies have shown the reasons for the
fast growing interest in ruthenium, as opposed to
platinum, as component of metal-based complexes.
Different ruthenium complexes with oxidation state
2? or 3? have demonstrated anticancer effects against
a variety of cancer types and more importantly against
metastatic cancers (Sava et al. 1999; Allardyce and
Dyson 2001; Alessio et al. 2004; Nowak-Sliwinska
et al. 2011).
The NAMI-A, imidazolium trans-[tetrachloro
(dimethylsulfoxide)(1H-imidazole)ruthenate(III) under-
went successfully phase I clinical trial on metastatic lung
cancer (Sava et al. 2003), as well as KP1019, indazolium
trans-[tetrachlorobis(1H-indazole)ruthenate(III) which
showed activity against colorectal tumor model and
several primary explanted human tumors (Berger et al.
1989). Similarly, ruthenium(II) arene complexes have
shown potent antiangiogenic and antimetastatic effect
(Clavel et al. 2015). Also, ruthenium/phosphine/diimine
complexes have been synthesized and shown promising
activity not only against cancer cells but bacteria as well
(Dos Santos et al. 2013).
The specific target of antitumor ruthenium com-
plexes remains to be elucidated, but it is generally
accepted that ruthenium complexes cytotoxicity is
related to their ability to bind DNA. However, several
ruthenium compounds have also shown to inhibit
DNA replication, induce SOS repair, reduce RNA
synthesis and inhibit angiogenesis (Brabec and
Novakova 2006; Nowak-Sliwinska et al. 2011).
Uptake of ruthenium complexes by tumor cells has
been suggested to occur through a mechanism medi-
ated by the iron transport protein transferrin (Li and
Qian 2002). Several studies have demonstrated an
upregulation in expression of the transferrin receptor
on metastatic and drug resistant tumours when com-
pared to their normal counterparts (Ryschich et al.
2004; Sahoo et al. 2004; Sahoo and Labhasetwar 2005;
Singh et al. 2011). Ruthenium is a transition metal of
the same group as platinum and iron but shows
important differences from platinum drugs, at the
same time, it shares many positive characteristics with
iron. Therefore it is possible that ruthenium mimics
iron in its way to bind molecules of biological
significance (Brabec and Novakova 2006). Further-
more, ruthenium complexes are thought to serve as
prodrugs where activation-by-reduction and aquation
are important steps related to the function of these
complexes inside the cells (Clarke et al. 1999; Bacac
et al. 2004; Jakupec et al. 2005). However, full
understanding on the mechanism of action of ruthe-
nium complexes still needs to be clarified.
Glioblastomas (GBM) are the most common brain
tumors in adults and the most deadly primary tumors of
the brain. It is characterized by its highly angiogenic
potential and invasiveness to the surrounding brain
tissue (Mangiola et al. 2013; Tanaka et al. 2013). GBM
is also associated with very poor survival resistance to
radiochemotherapy (Thuy et al. 2015). These charac-
teristics continue to challenge researchers and physi-
cians to find a successful strategy to treat patients
diagnosed with this type of tumor. Therefore, the
development of novel therapeutics agents able to inhibit
the growth and kill glioblastoma cancer cells is urgent
needed (Tanaka et al. 2013). Due to the demonstrated
properties of ruthenium-based complexes and its broad
range of activity against metastatic tumors, these
metallodrugs may be useful candidates in the treatment
of GBM tumors. Cisplatin based chemotherapy, one of
themost usedmetallodrug for cancer therapy has shown
limitations including: high toxicity, undesirable side
effects and resistance. This fact motivates the investi-
gation of new metal based cancer therapies. Although
association of cisplatin to radiotherapy (RT) has
improved prognosis for some cancers such as advanced
cervical cancer, esophageal cancer and cancer of head
and neck (Rose 2002; Van Hagen et al. 2012) few
advances were obtained in the treatment of glioblas-
toma. Unfortunately, GBM is associated with very poor
survival due to a high resistance to radiochemotherapy
(Thuy et al. 2015) including cisplatin. Therefore, the
development of novel therapeutics agents able to inhibit
the growth and kill glioblastoma cancer cells is urgent
needed (Tanaka et al. 2013). Due to the demonstrated
properties of ruthenium-based complexes and its broad
range of activity against metatastic tumors, these
metalodrugs emerge as an alternative for the treatment
of GBM tumors. Additionally, organometallic Ru
compounds have been shown to be radiosensitisers of
human cancers cells (Brabec and Novakova 2006;
Carter et al. 2016) and Ru isotopes have been pointed as
new potential radionuclides candidates for therapy
(Neves et al. 2005).
Radionuclide therapy (RNT) is rapidly growing
field in nuclear medicine and can be an alternative way
to decrease the toxicity and improve the specificity of
antitumoral drugs. Radionuclides are employed to
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deliver cytotoxic dose of radiation to diseased cells/
tissues (Kumar et al. 2016). We hypothesized that
combination of the known properties of ruthenium
complexes with the radiation produced by its neutron
activation could improve the antitumor activity of
these compounds offering more options for the use of
ruthenium metallodrugs. To the best of our knowl-
edge, this is the first report describing the use of
neutron activation strategy to generate radioactive
ruthenium complexes and to improve the activity
against tumor cells. In this work, we investigated the
effect of phosphine-ruthenium complexes before and
after neutron activation against GBM cell lines.
Materials and methods
Ruthenium compounds
The compounds of ruthenium(II): picolinate 2,20-
Bipyridine 1,4-bis(diphenylphosphino)butane hex-
afluorophosphate; [Ru(pic)(bipy)(dppb)]PF6 (1), 1,2-
bis(diphenylphosphino)ethane; [Ru(pic)(bipy)(dp-
pe)]PF6 (2), 1,10- bis(diphenylphosphino)ferrocene;
[Ru(pic)(bipy)(dppf)]PF6 (3) e 1,3- bis(diphenylphos-
phino)propane; [Ru(pic)(bipy)(dppp)]PF6 (4) were
synthesized at Sa˜o Carlos Federal University, Sa˜o
Carlos (SP/Brazil) and details was published else-
where (Dos Santos et al. 2013) and the structures are
shown in Fig. 1.
Stock solutions of 0.02 M of all compounds were
freshly prepared in dimethyl suphoxide (DMSO).
Final use concentration was adjusted by dilutions
keeping the DMSO concentration \0.5% in the
experiments.
Neutron activation of rutheniun phosphine
compounds
Samples of the compounds 1, 2, 3 and 4 were
irradiated for 8 h into polyethylene flasks carried out
on the Central position of the TRIGA (Training,
Research, Isotopes, General Atomics) MARK-I IPR-
R1 nuclear reactor at the Centro de Desenvolvimento
da Tecnologia Nuclear - Comissa˜o Nacional de
Energia Nuclear (CDTN-CNEN, Belo Horizonte,
Brazil), with a thermal neutronic flux of 4.1 9 1012
n cm-2 s-1. After neutron irradiation, samples were
submitted to gamma spectrometry in a system with an
HPGe detector CANBERRA 5019 and Gennie 2000
v2.0, CANBERRA software and a spectrometer
Wizard 2480 in order to characterize the spectra and
to determine the induced activity. The ruthenium
complexes 1, 2, 3 and 4 reached a specific activity in
the range of 1.32–1.55 Gbq/mol.
Cells lines and culture conditions
Malignant human Glioblastoma tumor cell lines U87
(p53 wild-type), T98 (p53 mutant) and normal cells
MRC5 (Human Fetal Lung Fibroblast) were obtained
from the American Type Culture Collection (ATCC,
USA). The cells were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM, Gibco), supple-
mented with 10% fetal bovine serum (FBS-Cultilab)
and antibiotics (50 U/ml penicillin, 50 lM strepto-
mycin), at 37 C in a humidified 5% CO2 atmosphere.
For all experiments, cells were seeded at appropriate
concentrations to ensure exponential growth.
Cytotoxic activity assay
The cytotoxicity of ruthenium(II) compounds was
determined by measuring mitochondrial activity as a
indicator of cell viability dependent on the reduction of
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide to formazan (Mosmann 1983). Cells
(1.5 9 103/well) were seeded in 200 ll complete
medium into 96-well microplates in triplicates. The
plates were incubated at 37 C in 5% CO2 for 24 h to
allow cell adhesion, prior to drug testing. All radioac-
tive or non-radioactive tested compounds were dis-
solved in sterile DMSO and diluted to reach final
concentrations ranging from 1 9 10-10 to 1 9 10-4
mol l-1. Cells were exposed to the compounds for a
24 h period and then, 0.5 mg ml-1 of MTT solution
was added to each well and further incubated for 4 h.
The precipitated formazan crystals were dissolved in
DMSO and the absorbance of produced color measured
spectrophotometrically at 570 nm. The results were
expressed as % viability of non-treated cell (control)
versus drug concentration and the concentration that
reduces cell viability by 50% (IC50) was calculated.
Morphological analysis of treated cells
After 24 h of treatment with different ruthenium
complexes at a final concentration of 1 9 10-5
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mol l-1 cells were washed once with buffered phos-
phate saline (PBS) followed by ice cold methanol
fixation for 20 min. Cells were washed again with PBS
and stained with 400 ng ml-1 DAPI 40,6-diamidine-2-
phenylindole dihydrochloride (Sigma-Aldrich) solu-
tion. After additional washes in PBS cell nuclei were
visualized on an inverted fluorescent microscopy
(Nikon: 385–410 nm) and photographs were taken.
Acridine orange-ethidium bromide (AO/EB)
doubling staining assay
Cells were treated with radioactive or non-radioactive
compounds 1, 2, 3 and 4. After 24 h incubation at
37 C in 5% CO2 atmosphere, cells were washed with
PBS and further incubated for 15 min in complete
medium supplemented with acridine orange (Sigma)
1 lg ml-1 and ethidium bromide (Sigma) 1 lg ml-1.
Medium was removed and cells were examined under
an inverted fluorescent microscope (Nikon:
530–560 nm). Photographs were taken with a Nikon
camera adapted to the microscope. Acridine orange
penetrates both living and dead cells emitting green
fluorescence, when intercalated into normal double-
stranded DNA, and red fluorescence, when bound with
damaged single stranded DNA. Ethidium bromide
penetrates only dead cells with damaged membranes
emitting red fluorescence. Four cell types could be
identified on the basis of fluorescence emission and
morphological aspect of chromatin condensation and
stained nuclei: (1) viable cells with uniformly bright
green nuclei fluorescence and an organized structure
(control); (2) early apoptotic cells with irregular green
nuclei with condensed chromatin and with apoptotic
Fig. 1 3D molecular structures of ruthenium complexes a Rudppba, b Rudppeb, c Rudppfb e d Rudppp, generated using the program
ORTEP (Oak ridge ellipsoid plot) (a, bPavan et al. 2010, 2011)
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bodies stained in red; (3) late apoptotic cells with
orange to red nuclei with highly fragmented chro-
matin; (4) uniformly orange to red nuclei with an
organized structure related to necrotic cells.
Measurement of reactive oxygen species (ROS)
generation
To evaluate the generation of reactive oxygen species
induced by ruthenium complexes, ROS accumulation
was detected using 20,70-dichlorodihydrofluorescein
diacetate DCFH-DA (Sigma-Aldrich). DCFH-DA is a
non-fluorescent compound which upon taken up by
passive diffusion into cells is hydrolyzed by esterases
to yeld non-permeable DCFH. In the presence of ROS,
DCFH is oxidized to the fluorescent DCF (Thannickal
and Fanburg 2000). Cells were treated with 1 9 10-5
mol l-1 of ruthenium complexes for 24 h and then
incubated with 1 9 10-5 mol l-1 DCFH-DA for
30 min at 37 C. Following incubation, the cells were
washed twice with PBS and examined under the
fluorescent microscope Nikon coupled with a digital
camera at excitation and emission wavelengths of 488
and 525 nm, respectively. Quantitative analysis of
fluorescence was performed using ImageJ software
(ImageJ, National Institute of health, Bethesda, MD,
USA) and expressed as percentages of DCF-DA
fluorescence of the corresponding control.
Statistical analysis
Data were expressed as mean ± standard deviation
(SD) of three independent experiments performed in
triplicates. One-tailed unpaired Student‘s t test was
used for significance testing using a p value of 0.05.
Prisma Graph Pad version 5.01(Graphpad Software
Inc., La Jolla, CA) was used for the statistical analysis.




Non-radioactives compounds IC50 (lM)
U87 T98 MRC5
[Ru(pic)(bipy)(dppb)]PF6 (1) 16.1 ± 3.3 11.9 ± 5.9 41.0 ± 10.1
[Ru(pic)(bipy)(dppe)]PF6 (2) 27.8 ± 11.7 19.0 ± 5.9 82.1 ± 9.1
[Ru(pic)(bipy)(dppf)]PF6 (3) 4.0 ± 8.5 3.0 ± 0.7 8.9 ± 2.3
[Ru(pic)(bipy)(dppp)]PF6 (4) 4.9 ± 2.5 1.5 ± 0.5 1.47 ± 0.6
Cisplatin 1.8 ± 0.2 5.3 ± 1.9 5.05 ± 0.7
Table 2 Cytotoxicity of neutron activated ruthenium complexes against glioma cells
Radioactive compounds IC50 (lM)
U87 T98 MRC5
[103Ru(pic)(bipy)(dppb)]PF6 (1) 2.4 9 10-4 ± 1.3 9 10-4 3.4 9 10-4 ± 9.4 9 10-5 3.9 9 10-4 ± 1.0 9 10-4
[103Ru(pic)(bipy)(dppe)]PF6 (2) 2.3 9 10-4 ± 1.5 9 10-4 5.2 9 10-4 ± 9.4 9 10-5 2.0 9 10-4 ± 5.5 9 10-5
[103Ru(pic)(bipy)(dppf)]PF6 (3) 4.2 9 10-4 ± 1.7 9 10-4 5.4 9 10-4 ± 2.3 9 10-5 3.8 9 10-4 ± 4.1 9 10-5
[103Ru(pic)(bipy)(dppp)]PF6 (4) 3.1 9 10-4 ± 1.7 9 10-5 6.2 9 10-4 ± 8.7 9 10-5 4.7 9 10-4 ± 0
Table 3 Selectivity index of non-radioactive and neutron
activated ruthenium complexes in glioma cells
Selectivity index
Compounds Non-radioactive Radioactive
U87 T98 U87 T98
[Ru(pic)(bipy)(dppb)]PF6 (1) 2.55 3.45 1.63 1.14
[Ru(pic)(bipy)(dppe)]PF6 (2) 2.95 4.32 0.87 0.39
[Ru(pic)(bipy)(dppf)]PF6 (3) 2.23 2.91 0.90 0.70
[Ru(pic)(bipy)(dppp)]PF6 (4) 0.29 0.98 1.52 0.76
Cisplatin 2.87 0.95 – –
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Results
Cytotoxic activity against malignant glioma cells
All ruthenium(II)/phosphine/diimine compounds
evaluated showed strong antiproliferative and cyto-
toxic activity on glioma cells. Compounds [Ru(pic)
(bipy)(dppf)]PF6 and [Ru(pic)(bipy)(dppp)]PF6 were
the most active with IC50 values of 3.98 ± 0.85 lM;
4.92 ± 2.46 lM for U87 cells and 3.05 ± 0.72 lM;
1.49 ± 0.50 lM for T98 cells respectively (Table 1).
All the compounds tested for both U87 and T98 cell
lines, except [Ru(pic)(bipy)(dppp)]PF6, showed smal-
ler IC50 values than that determined for the normal
control cell line MRC5. Upon neutron activation of
ruthenium complexes the cytotoxicity greatly
increased corresponding to IC50 values around
10,000 fold smaller (Table 2).
Ruthenium complexes presented selectivity index
(SI = IC50 MRC5/IC50 tumor cell) ranging from 0.29
to 4.32. These values were comparable to that
determined for cisplatin in U87 cells. However,
Selectivity indexes were higher and better than
cisplatin for T98 tumor cell line harboring the tumor
suppressor TP53 mutant gene. [Ru(pic)(bipy)(dp-
pe)]PF6 was the compound that showed the highest
SI among the ruthenium compound tested (Table 3).
Morphological analysis of tumor cells treated
with unmodified and neutron activated ruthenium
complexes
All ruthenium(II)/phosphine/diimine compounds
tested induced morphological alterations on glioma
cell lines independent of the p53 protein status.
Morphological and culture behavior alterations such
as cytoplasmic and cell membrane retraction changing
the spindle-like cell shape, commonly seen in normal
cultured glial derived cells, leading to a transition from
the characteristic fusiform to rounded shape cells,
Fig. 2 Effect of non-radioactive ruthenium(II) complexes 1, 2,
3 and 4 on the morphology of T98, U87 and MRC5 cell lines.
a After 24 h treatment, morphological changes such as cell
rounding and shrinkage (black closed arrow), irregularities on
cell membrane (black open arrow) and blebs formation (white
arrow) can be observed under phase contrast. b Cells were
treated with were stained with DAPI. Nuclear condensation
(arrows), nuclear fragmentation (white asterisks) and formation
of apoptotic bodies (yellow asterisks) were seen in cells treated
with these compounds Concentration: 10 lM. Amplification:
9400
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detachment from the plate culture, cell shrinkage and
membrane blebs formation. After DAPI staining,
chromatin condensation, nuclear fragmentation and
formation of apoptotic bodies could be also observed
(Fig. 2). Neutron activated compounds also induced
the same morphological alterations at lower concen-
trations (Fig. 3).
Determination of the type of cell death induced
by ruthenium complexes using acridine-orange/
ethidium bromide (AO/EB) double staining
In order to correlate the observed morphological
alterations with decreased cell viability and to identify
early/late apoptotic events, necrose and autophagy, we
double stained cells with acridine orange (AO) and
ethidium bromide (EB) after 24 h treatment. Viable
cells could be identified by bright homogeneous green
nuclei in untreated cells (AO). Cells presenting early
apoptotic events were identified by irregularly
structured green nuclei with condensed chromatin
and orange or light red patches. Late apoptotic cells
contained positively stained nuclei with both dyes (EB
and AO) appearing orange or light red with the
apoptotic bodies. Nuclei of necrotic cells had intact
chromatin and appeared red. In control cells, all nuclei
appeared green with a regular spherical or oval
structure and chromatin organization (Fig. 4).
Measurement of reactive oxygen species
Generation of reactive oxygen species was determined
by detection and measurement of fluorescence pro-
duced by the oxidation of the non-fluorescent 20,70-
dichlorodihydrofluorescein-diacetate (DCFH-DA)
into the fluorescent 20,70-dichlorodihydrofluorescein
(DCF) by free radicals inside the cell. As shown in
Fig. 4, treatment of glioma cells with ruthenium
complexes for 24 h resulted in marked increase of
the intracellular ROS levels (Fig. 5). These levels
Fig. 3 T98, U87 andMRC5 cells treated with neutron activated
ruthenium(II) complexes 1, 2, 3 and 4. a After 24 h treatment,
morphological changes such as cell rounding and shrinkage
(black closed arrow), irregularities in membrane (black open
arrow) and blebs formation (white arrow) could be observed
under phase contrast microscope. b Cells treated were stained
with DAPI and nuclei examined under fluorescent microscope.
Nuclear condensation (arrows), nuclear fragmentation (white
asterisks) and formation of apoptotic bodies (yellow asterisks)
were seen in cells treated with these compounds. Concentration:
10 lM. Amplification: 9400
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were higher in tumor cells than in the control MRC5
cells depending on the compound analyzed.
Discussion
New ruthenium(II)/phosphine/diimine compounds
have been synthesized and their biological activities
evaluated. Similar to other ruthenium complexes,
these new compounds have demonstrated promising
activity on glioblastoma tumor cells bearing different
genetic backgrounds. Furthermore the compounds
tested here showed better activity than the well-known
cisplatin drug. Ruthenium based compounds showed
IC50 in the range of micromolar concentrations.
However, upon neutron activation we could observe
a decrease of approximately 10,000 fold in the IC50
values demonstrating that this approach largely
increased the toxicity of the primary compound and
revealing a great potential for neutron activation of
ruthenium based metallodrugs as a strategy to increase
cytotoxicity of these compounds. To our knowledge
this is the first report showing the use of this approach
to try to increase the cytotoxicity of ruthenium
compounds. Even considering the fact that the
increased cytotoxicity affected the normal cell line
used MRC5, still this strategy may be useful after
some modifications targeting ruthenium complexes to
a more specific site into cancer cells.
Some of the advantages of using ions of transition
metals such as ruthenium instead platinum include the
availability of additional coordination sites in octahe-
dral complexes and altered shape of the complex. In
addition, the changes in oxidation state, alterations in
ligand affinity, substitution kinetics and potential for
photodynamic approaches to therapy turn these com-
plexes theoretically attractive. Considering the octa-
hedral structure of ruthenium(II) complexes as
opposed to the square-planar geometry of platinum(II)
compounds, ruthenium(II) anticancer complexes
probably function in a way different from that of
cisplatin. Our results suggested that in addition to the
Fig. 4 Detection of cell death induced by ruthenium com-
plexes. Cells T98, U87 and MRC5 were treated with ruthenium
complexes (10 lM) for 24 h followed by double staining with
acridina orange/ethidium bromide. Evidence of acid
autophagossomes (yellow arrow), apoptosis (white arrow) and
some necrotic cells (red arrows). a Treatment non-radioactive.
b Treatment with neutron activated compounds. Amplification:
9400
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known DNA affinity of ruthenium complexes, the
generation of reactive oxygen species may be other
mechanism by which ruthenium can induce cell death.
In fact, ROS production is associated in many forms of
apoptosis through mediation of signaling transduction
processes (Suzuki et al. 1997). We showed that
neutron activated ruthenium compounds were able to
generate more ROS than their counterparts which
correlated well with their increased cytotoxicity.
Employment of radiotherapeutical agents has
always been an important strategy to treat cancer
patients. Furthermore, the use of molecular carriers
that may provide vehicles for selective deposition of
radioactivity in the tumor region has received great
interest in the past decades. Ruthenium isotopes decay
by electron capture and emit low energy electrons
consisting mainly of Auger and Coster–Kronig elec-
trons. It is well-known that incorporation of Auger–
Fig. 5 Generation of reactive oxygen species (ROS) in cells
treated with compounds 1, 2, 3 and 4. After 24 h treatment cells
were stained with DCF-DA. Treated glioma cells show
increased fluorescence intensity (amplification 9400). a Non-
radioactive treatment. b Radioactive Treatment. C and D show
ROS production (measured as relative fluorescence increase) in
cells treated with compounds 1, 2, 3 and 4. Concentration:
(10 lM). *Statistically significant difference from T98;
**statistically significant difference from MRC5
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electron emmiters within the cell nucleus produce high
radiotoxicity (Volkert et al. 1991). This is due to the
deposition of a concentrated amount of energy emitted
in the form of a shower of Auger and Coster-Kronig
electrons with energies ranging from a few to several
hundred electron volts into an extremely small volume
within the nuclear DNA (Makrigiorgos et al. 1990).
The higher cytotoxicity showed in this work after
neutron activation of ruthenium compounds may be
due to this mechanism. In order to be used in
radionuclide therapy methods of selective guidance
to target cells and subsequent introduction of these
radionuclides with good selectivity into the nucleus
must be found. Ruthenium complexes have shown to
have high affinity to DNA which could be a way to
target the radionuclide to the nucleus. In fact, 106Ru
has been reported as a good strategy in brachytherapy
to treat uveal melanoma (Barker et al. 2014; Naser-
ipour et al. 2016). Nevertheless, further studies are
necessary to better evaluate the potential of neutron




glioblastoma cell proliferation and show IC50 in the
range of micromolar concentrations. Neutron activa-
tion of these compounds is able to increase their
cytotoxicity and may be a good strategy to radionu-
clide therapy.
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